| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3804 | Nsc-8891 | Tyrosyl-DNA phosphodiesterase (Tdp1) inhibitor |
|
| DCC3805 | Nsc-9037 | First-in-class probe of Rad6 function, inhibiting Rad6 function and Rad6-Rad18 interaction in the PCNA ubiquitination cascade |
|
| DCC3806 | nsc-96626 | Novel B-Raf(V600E) inhibitor |
|
| DCC3807 | Nsi-189 Phosphate | Novel stimulator of neurogenesis of human hippocampus-derived neural stem cells in vitro and in vivo. |
|
| DCC3808 | Nsmase2-in-1 | Novel inhibitor of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases |
|
| DCC3809 | Nsp-116 | Novel free radical scavenger, against light-induced photoreceptor cell damage |
|
| DCC3810 | Nti-007 | Potent anti-HBV agent, targeting the NTCP-APOA1-HBx-Beclin1-mediated autophagic pathway |
|
| DCC3811 | Ntrc-739 | Novel nonpeptide selective ligand for NTS2 |
|
| DCC3812 | Ntrc-808 | Novel nonpeptide potent and selective partial agonist of the Neurotensin receptor type 2 (NTS2) |
|
| DCC3813 | Ntrd22 | Novel Allosteric Modulator of RNA Binding Targeting the N-Terminal Domain of TDP-43 |
|
| DCC3814 | Ntr-responsive Protac 17-1 | The first NTR-responsive PROTAC, incorporating the caging group on the Von Hippel-Lindau (VHL) E3 ubiquitin ligase ligand, efficiently degrading the EGFR protein and subsequently exert antitumor efficacy |
|
| DCC3815 | Ntz-15 | Novel potent STAT3 inhibitor, exhibiting much improved in vivo pharmacokinetic parameters in rats and efficacies against proliferations in multiple cancer cell lines |
|
| DCC3816 | Ntz-24 | Novel potent STAT3 inhibitor |
|
| DCC3817 | Ntzdpa | Novel potent and selective non-thiazolidinedione partial Peroxisome_proliferator-activated_receptor>PPARγ agonist, acting as an antibiotic effectively against bacterial persisters |
|
| DCC3818 | Nu6155 | Novel potent CDK2 inhibitor |
|
| DCC3819 | Nuc013 | Novel DNA methytransferase inhibitor, be significantly safer and more effective than decitabine in xenograft models of human leukemia and colon cancer |
|
| DCC3820 | Nucc-201177 | Novel highly potent and selective MEK4 inhibitor |
|
| DCC3821 | Nucc-474 | Novel potent activin antagonist |
|
| DCC3822 | Nucc-555 | First-in-class activin antagonist, specifically binding to ALK4, which opens a completely new approach to inhibiting the activity of TGF-beta receptor superfamily members |
|
| DCC3823 | Nucleocidin | Nucleosidic antibiotic |
|
| DCC3824 | Nuod-in-25 | Novel inhibitor of Helicobacter pylori , targeting H. pylori's respiratory complex I subunit NuoD |
|
| DCC3825 | Nurf Inhibitor Bz1 | Novel Potent Cell-Active Inhibitor of the Nucleosome Remodeling Factor (NURF) via BPTF Bromodomain Inhibition |
|
| DCC3826 | Nusb-nuse Inhibitor-22 | Novel Inhibitor of the NusB-NusE Protein-Protein Interaction with Antibiotic Activity |
|
| DCC3827 | Nusb-nuse Interaction Inhibitor-1 | Novel modulator of the NusB-NusE interaction |
|
| DCC3828 | Nutlin-1 | p53-MDM2 binding inhibitor; p-Glycoprotein (p-gp) transport substrate; Antitumer agent |
|
| DCC3829 | Nutlin-2 | Potent and selective p53-MDM2 binding inhibitor |
|
| DCC3830 | Nv2899 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
| DCC3831 | Nv2907 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
| DCC3832 | Nv2909 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
| DCC3833 | Nv2913 | Novel translational readthrough-inducing drug (TRID), rescuing the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs) |
|
